Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | SCN2B | O60939 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363968 | 0.92 | SCN9A (0.55) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL10198133 | 0.87 | SCN9A (0.46) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL364788 | 0.86 | SCN9A (0.46) | SCN9ASCN5A | |
| SCHEMBL363186 | 0.85 | SCN9A (0.46) | SCN9ASCN5A | |
| Lithium SCHEMBL364790 | 0.84 | SCN9A (0.46) | SCN9ASCN5A | |
| SCHEMBL15094290 | 0.83 | SCN9A (0.44) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL16175148 | 0.83 | SCN9A (0.47) | SCN9ASCN5A | |
| SCHEMBL365758 | 0.82 | SCN9A (0.55) | SCN9ASCN5A | |
| SCHEMBL15543236 | 0.81 | SCN9A (0.67) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL364266 | 0.81 | SCN9A (0.71) | SCN9ASCN5ASCN2BSCN1ASCN1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291514-A1 | N-Aminosulfonyl Benzamides | PFIZER LIMTED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150291514-A1 | N-Aminosulfonyl Benzamides | PFIZER LIMTED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150291514-A1 | N-Aminosulfonyl Benzamides | PFIZER LIMTED (GB) | 2015-10-15 | — | — | US | disclosed |
| EP-2800740-A1 | N-AMINOSULFONYL BENZAMIDES | Pfizer Limited (GB) | 2014-11-12 | — | — | EP | disclosed |
| WO-2013102826-A1 | N-AMINOSULFONYL BENZAMIDES | PFIZER LIMITED (GB) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013102826-A1 | N-AMINOSULFONYL BENZAMIDES | PFIZER LIMITED (GB) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291514-A1 | N-Aminosulfonyl Benzamides | SCN7A, SCN2B, SCN1B | SCN9A 14/4885SCN5A 5/4885SCN2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.